Parnell Pharmaceuticals Holdings (PARN) & Mylan N.V. (MYL) Critical Comparison
Parnell Pharmaceuticals Holdings (NASDAQ: PARN) and Mylan N.V. (NASDAQ:MYL) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, analyst recommendations, profitability, dividends and valuation.
Insider & Institutional Ownership
16.9% of Parnell Pharmaceuticals Holdings shares are held by institutional investors. Comparatively, 72.0% of Mylan N.V. shares are held by institutional investors. 0.7% of Mylan N.V. shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares Parnell Pharmaceuticals Holdings and Mylan N.V.’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Parnell Pharmaceuticals Holdings||N/A||N/A||N/A||N/A||N/A|
|Mylan N.V.||$12.01 billion||1.41||$3.92 billion||$1.22||25.80|
Mylan N.V. has higher revenue and earnings than Parnell Pharmaceuticals Holdings.
This is a summary of current recommendations and price targets for Parnell Pharmaceuticals Holdings and Mylan N.V., as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Parnell Pharmaceuticals Holdings||0||0||0||0||N/A|
Mylan N.V. has a consensus price target of $43.27, indicating a potential upside of 37.47%. Given Mylan N.V.’s higher probable upside, analysts plainly believe Mylan N.V. is more favorable than Parnell Pharmaceuticals Holdings.
Risk & Volatility
Parnell Pharmaceuticals Holdings has a beta of 0.14, suggesting that its share price is 86% less volatile than the S&P 500. Comparatively, Mylan N.V. has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500.
This table compares Parnell Pharmaceuticals Holdings and Mylan N.V.’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Parnell Pharmaceuticals Holdings||-130.46%||-83.86%||-43.24%|
Mylan N.V. beats Parnell Pharmaceuticals Holdings on 10 of the 10 factors compared between the two stocks.
Parnell Pharmaceuticals Holdings Company Profile
Parnell Pharmaceuticals Holdings Limited is a veterinary pharmaceutical company. The Company is focused on developing, manufacturing and commercializing animal health solutions. The principal activities of the Company include manufacture for global sale of animal pharmaceutical product, and research and development of pharmaceutical products for global animal health markets. The Company operates through four segments: Companion Animal, Production Animal-U.S., Production Animal-Rest of World and Manufacturing Operations. It augments its pharmaceutical products with its FETCH and mySYNCH software platforms. It offers disease-modifying product, Zydax, for the treatment of osteoarthritis (OA). Its reproductive hormone products include estroPLAN and GONAbreed. It has a nutraceutical product, Glyde. It also markets a non-steroidal anti-inflammatory drug (NSAID), called Tergive. It is developing a pipeline of clinical drug candidates, such as PAR 121, PAR 122, PAR 101, PAR 081 and PAR 061.
Mylan N.V. Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty. Its Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, cream or ointment form, as well as API. Its Specialty segment is focused on respiratory and allergy therapies. The EpiPen Auto-Injector, which is used in the treatment of severe allergic reactions, is an epinephrine auto-injector. Its Perforomist Inhalation Solution is a long-acting beta2-adrenergic agonist indicated for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder (COPD) patients. The Company also markets ULTIVA, which is an analgesic agent.
Receive News & Ratings for Parnell Pharmaceuticals Holdings Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Parnell Pharmaceuticals Holdings Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.